Systematic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: Present status and future directions

Expert Opinion on Investigational Drugs

Volumn 16, Issue 7, 2007, Pages 1059-1068

  Richards, Donald A ^a,b   Boehm, Kristi A ^a   Anthony, Stephen P ^a,c  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Tyler Cancer Center   (United States)

^c HonorHealth and the Scottsdale Lincoln Health Network   (United States)

Author keywords

Adenocarcinoma; Gastric; Histologies; Targeted agent

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE; BEVACIZUMAB; BRYOSTATIN; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; EPOTHILONE DERIVATIVE; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; IXABEPILONE; LAPATINIB; MATUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; TRICHOSTATIN A; UNINDEXED DRUG; VITAMIN; VORINOSTAT; ANTINEOPLASTIC AGENT; NEW DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ALCOHOL CONSUMPTION; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DIETARY INTAKE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GASTRITIS; HELICOBACTER INFECTION; HUMAN; HYPERTENSION; LEUKOPENIA; LOW DRUG DOSE; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW; RISK FACTOR; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; ADENOCARCINOMA; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FORECASTING; INTRAVENOUS DRUG ADMINISTRATION; LOWER ESOPHAGUS SPHINCTER; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; STOMACH TUMOR; SURVIVAL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; ESOPHAGOGASTRIC JUNCTION; FEMALE; FORECASTING; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34447508432     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.7.1059     Document Type: Review

References (56)

1. VARADHACHARY G, AJANI JA: Gastric cancer. Clin. Adv. Hematol. Oncol. (2005) 3(2):118-124.
2. CREW KD, NEUGUT AI: Epidemiology of gastric cancer. World J. Gastroenterol. (2006) 12(3):354-362.
3. PERA M: Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. (2000) 155:1-14.
4. HOCHWALD SN, KIM S, KLIMSTRA DS, BRENNAN MF, KARPEH MS: Analysis of 154 actual 5-year survivors of gastric cancer. J. Gastrointest. Surg. (2000) 4(5):520-525.
5. SAKAGUCHI T, WATANABE A, SAWADA H et al.: Characteristics and clinical outcome of proximal-third gastric cancer. J. Am. Coll. Surg. (1998) 187(4):352-357.
6. KIM DY, JOO JK, PARK YK, RYU SY, KIM YJ, SIM SK: Predictors of long-term survival in node-positive gastric carcinoma patients with curative resection. Langenbecks Arch. Surg. (2007) 392(2):131-134.
7. MARUYAMA M, TAKESHITA K, ENDO M, DEAKIN M, MOOSSA A: Clinicopathological study of gastric carcinoma in high- and low-mortality countries: comparison between Japan and the US. Gastric Cancer (1998) 1(1):64-70.
8. WANG HH, ANTONIOLI DA, GOLDMAN H: Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum. Pathol. (1986) 17(5):482-487.
9. FENOGLIO-PREISER CM, WANG J, STEMMERMANN GN, NOFFSINGER A: TP53 and gastric carcinoma: a review. Hum Mutat. (2003) 21(3):258-270.
10. ALBINO AP, JAEHNE J, ALTORKI N et al.: Amplification of HER-2/ neu gene in human gastric adenocarcinomas: correlation with primary site. Eur. J. Surg. Oncol. (1995) 21(1):56-60.
11. EL-RIFAI W, POWELL SM: Molecular biology of gastric cancer. Semin. Radiat. Oncol. (2002) 12(2):128-140.
12. JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics. CA Cancer J. Clin. (2006) 56(2):106-130.
13. WAGNER AD, GROTHE W, HAERTING J, KLEBER G, GROTHEY A, FLEIG WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. (2006) 24(18):2903-2909.
14. KHAMLY K, JEFFORD M, MICHAEL M, ZALCBERG J: Recent developments in the systemic therapy of advanced gastroesophageal malignancies. Expert Opin. Investig, Drugs (2006) 15(2):131-153.
15. CUNNINGHAM D, RAO S, STARLING N et al.: Randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):LBA4017.
16. AL-BATRAN S, HARTMANN J, PROBST S et al.: A randomized Phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). J. Clin. Oncol. 2006 ASCO Annual Meeting proceedings Part I (2006) 24(18S: June 20 Supplement):LBA4016.
17. VAN CUTSEM E, MOISEYENKO VM, TJULANDIN S et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. (2006) 24(31):4991-4997.
18. RICHARDS DA, WILFONG L, REZNICK D et al.: Phase II multicenter trial of docetaxel+oxatiplatin in stage IV gastroesophageal and/or stomach cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):4071.
19. MACDONALD JS, SMALLEY SR, BENEDETTI J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. (2001) 345(10):725-730.
20. CUNNINGHAM D, ALLUM WH, STENNING SP et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. (2006) 355(1):11-20.
21. AJANI JA: Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. (2006) 33(Suppl. 1):117-120.
22. KIM JH, LEE KW, JUNG Y et al.: Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci. (2005) 96(6):365-371.
23. BAJETTA E, CELIO L, BUZZONI R et al.: Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann. Oncol. (2003) 14(10):1543-1538.
24. KIM HK, SONG KS, PARK YS et al.: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur. J. Cancer (2003) 39(2):184-191.
25. BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. (1993) 53(19):4727-4735.
26. TIAN X, SONG S, WU J, MENG L, DONG Z, SHOU C: Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem. Biophys. Res. Commun. (2001) 286(3):505-512.
27. CHAE Y, KIM J, BAEK J et al.: Vascular endothelial growth factor (VEGF) -460T > C polymorphism is associated with prognosis of patients with early stage gastric cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedingy Part I (2006) 24(18S: June 20 Supplement):4019.
28. SHAH MA, RAMANATHAN RK, ILSON D et al.: Final results of a multicenter Phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI 6447). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):4020.
29. 2A receptors in cardiovascular regulation in anaesthetized rats. Br. J. Pharmacol. (1999) 128(3):530-542.
30. BOKU N, OHTSU A, SHIMADA Y et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. (1999) 17(1):319-323.
31. LAU SC, ROSA DD, JAYSON G: Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. Curr. Opin. Mol. Ther. (2005) 7(5):493-501.
32. ROJO F, ALBANELL J, SAULEDA S, BASELGA J: Characterization of epidermal growth factor (EGF) receptor and transforming growth factor (TGF)-α expression in gastric cancer and its association with activation of mitogen-activated protein kinase (MAPK). Proc. Am. Soc. Clin. Oncol. (2001) 20:1717.
33. KOPP R, RUGE M, ROTHBAUER E et al.: Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. (2002) 22(2B):1161-1167.
34. GARCIA I, VIZOSO F, MARTIN A et al.: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. (2003) 10(3):234-241.
35. KIM T: Technology evaluation: Matuzumab, Merck KGaA. Curr. Opin. Mol. Ther. (2004) 6(1):96-103.
36. YONEMURA Y, NINOMIYA I, OHOYAMA S et al.: Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer (1991) 67(11):2914-2918.
37. TANNER M, HOLLMEN M, JUNTILA TT et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. (2005) 16(2):273-278.
38. OUGOLKOV A, YAMASHITA K, BILIM V, TAKAHASHI Y, MAI M, MINAMOTO T: Abnormal expression of E-cadherin, β-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int. J. Colorectal Dis. (2003) 18(2):160-166.
39. MULLER-TIDOW C, SCHWABLE J, STEFFEN B et al.: High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin. Cancer Res. (2004) 10(4):1241-1249.
40. DOI T, KOIZUMI W, SIENA S et al.: Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1839) in pretreated patients with metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:1036.
41. KORTMANSKY J, SCHWARTZ GK: Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. (2003) 21(6):924-936.
42. SCHWARTZ GK, ILSON D, SALTZ L et al.: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. (2001) 19(7):1985-1992.
43. SATO S, KAJIYAMA Y, SUGANO M et al.: Alvocidib (flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis. Surg. Oncol. (2006) 15(2):107-113.
44. RAJU U, ARICA H, KOTO M et al.: Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependant kinases. Radiother. Oncol. (2006) 80(2):185-191.
45. DIPETRILLO T, MILAS L, EVANS D et al.: Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a Phase I study. Am J. Clin. Oncol. (2006) 29(4):376-379.
46. BODDY AV, PLUMMER ET, TODD R et al.: A Phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3- and 2-weekly schedules. Clin. Cancer Res. (2005) 11(21):7834-7840.
47. AJANI JA, SAFRAN H, BOKEMEYER C et al.: A multi-center Phase II study of BMS-247550 (ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest. New Drugs (2006) 24(5):441-446.
48. BIAMONTE MA, SHI J, HONG K et al.: Orally active purine-based inhibitors of the heat shock protein 90. J. Med. Chem. (2006) 49(2):817-828.
49. YU J, LEUNG WK, EBERT MP et al.: Increased expression of surviving in gastric cancer patients and first degree relatives. Br. J. Cancer (2002) 87(1):91-97.
50. LEE GH, JOO YE, CHUNG IJ et al.: Expression of survivn in gastric cancer and its relationship with tumor angiogenesis. Eur. J. Gastroenterol. Hepatol. (2006) 18(9):957-963.
51. WACHECK C, CEJKA D, SEIGHART W et al.: Mcl-1 is a relavent molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol. Ther. (2006) 5(10):1348-1354.
52. OSAKI M, KASE S, ADACHI K, TAKEDA A, HASHIMOTO K, ITO H: Inhibition of the Pl3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J. Cancer Res. Clin. Oncol. (2004) 130(1):8-14.
53. ZHANG X, YASHIRO M, REN J, HIRAKAWA K: Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol. Rep. (2006) 16(3):563-568.
54. POZZO C, BARONE C, SZANTO J et al.: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric-junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol. (2004) 15(12):1773-1781.
55. KANG Y, KANG WK, SHIN DB et al.: Randomized Phase III trial of capecitabine/cisplatin (XP) versus continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J. Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S):LBA4018.
56. DANK M, ZALUSKI J, BARONE C et al.: Randomized Phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) versus CDDP + 5FU in 1st-line advanced gastric cancer patients. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23(16S, Part I of II):4003.